ORGO Sales Drop 23%
Organogenesis ( NASDAQ:ORGO ) , a regenerative medicine company specializing in advanced wound care and surgical and sports medicine products, reported Q2 2025 results on August 7, 2025. The standout news: GAAP revenue was $100.8 million for Q2 2025, missing analyst estimates of $103.4 million ( ...
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Blue Gold ( NASDAQ:BGL ) , FB Financial ( NYSE:FBK )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Simulations Plus, Inc SLP fell sharply in pre-market trading after the company reported downbeat third-quarter sales and cut its FY2025 EPS guidance.
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Ansys ( NASDAQ:ANSS ) , BloomZ ( NASDAQ:BLMZ )
Shares of The Trade Desk, Inc. TTD rose sharply in pre-market trading following the announcement of its inclusion in the S&P 500 index. This development comes after the S&P Dow Jones Indices revealed that The Trade Desk would replace ANSYS Inc. ANSS in the S&P 500, effective from the market open ...
Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday - Cameco ( NYSE:CCJ ) , AST SpaceMobile ( NASDAQ:ASTS )
U.S. stocks were mixed, with the Dow Jones index falling around 150 points on Monday. Shares of Warner Bros. Discovery, Inc. WBD rose sharply in today's session.
Organogenesis ( ORGO ) Reports Q1 Loss, Lags Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of -425% and 4.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness
Organogenesis recommends CMS also implement an integrated coverage and payment policy Organogenesis recommends CMS also implement an integrated coverage and payment policy ...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
CANTON, Mass., April 07, 2025 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, ...
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Organogenesis ( ORGO ) Q4 2024 Earnings Call Transcript
ORGO earnings call for the period ending December 31, 2024.
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
CANTON, Mass., Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, ...
Organogenesis Expands Manufacturing Capacity to Support Future Growth - Organogenesis Hldgs ( NASDAQ:ORGO )
CANTON, Mass., Nov. 22, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc.
Organogenesis Expands Manufacturing Capacity to Support Future Growth
CANTON, Mass., Nov. 22, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, ...
Organogenesis Commends Final LCDs - Organogenesis Hldgs ( NASDAQ:ORGO )
CANTON, Mass., Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ORGO, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, commends today's ...
Organogenesis Commends Final LCDs
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination ...
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday - Paymentus Holdings ( NYSE:PAY )
U.S. stocks were mixed, with the Nasdaq Composite falling around 50 points on Wednesday. Shares of Paymentus Holdings, Inc. PAY rose sharply in today's session after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates.
Organogenesis ( ORGO ) Q3 2024 Earnings Call Transcript
ORGO earnings call for the period ending September 30, 2024.
Organogenesis ( ORGO ) Tops Q3 Earnings and Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of 550% and 5.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis - Organogenesis Hldgs ( NASDAQ:ORGO )
CANTON, Mass., Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc.
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
CANTON, Mass., Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, ...
Bioventus ( BVS ) Matches Q3 Earnings Estimates
Bioventus (BVS) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 - Organogenesis Hldgs ( NASDAQ:ORGO )
CANTON, Mass., Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc.
Organogenesis ( ORGO ) Shows Fast-paced Momentum But Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - CareDx ( NASDAQ:CDNA )
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday. Shares of CareDx, Inc CDNA fell sharply in today's pre-market trading as the company reported preliminary results for the third quarter.
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
CANTON, Mass., Oct. 01, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, ...
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September - Organogenesis Hldgs ( NASDAQ:ORGO )
CANTON, Mass., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ORGO, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced ...
Organogenesis ( ORGO ) Q2 2024 Earnings Call Transcript
ORGO earnings call for the period ending June 30, 2024.
Organogenesis ( ORGO ) Reports Q2 Loss, Tops Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of -550% and 6.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis Shares ReNu® Program Update - Organogenesis Hldgs ( NASDAQ:ORGO )
On track to submit ReNu BLA by the end of 2025 Enrollment in second Phase 3 complete; significantly ahead of expectations Subgroup analysis demonstrated most severe ( KL4 ) subjects responded comparably to moderate ( KL3 ) CANTON, Mass., Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis ...
Karyopharm Therapeutics ( KPTI ) Reports Q2 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 31.03% and 18.62%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Tissue Engineering Market Size is Expected to Reach USD 12.43 Billion by 2032, Growing at a CAGR of 14.40%: Straits Research
New York, United States, July 18, 2024 ( GLOBE NEWSWIRE ) -- As per the Latest Report by Straits Research, the global tissue engineering market size was valued at USD 4,333.61 million in 2023. It is projected to reach USD 12,425.62 million by 2032, growing at a CAGR of 14.40% during the forecast ...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
CANTON, Mass., July 15, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ...
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
CANTON, Mass., June 06, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ...
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday - Groupon ( NASDAQ:GRPN )
U.S. stocks were mostly higher, with the Dow Jones gaining over 100 points on Friday. Shares of Genpact Limited G rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and raised its FY24 EPS range.
Organogenesis ( ORGO ) Q1 2024 Earnings Call Transcript
ORGO earnings call for the period ending March 31, 2024.
ALNY: 4 Biotech Stocks to Watch Closely in May
As biotechnology continues to propel breakthroughs in pharmaceuticals, genomics, and medical devices, the spotlight is increasingly drawn to this sector for growth and portfolio diversification.
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 - Organogenesis Hldgs ( NASDAQ:ORGO )
CANTON, Mass., April 16, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc.
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ...
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( NASDAQ: ORGO ) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ...
Why Organogenesis Holding Stock Plummeted by 18% Today
A double miss put the wound care specialist's shares on the sick list.
Organogenesis ( ORGO ) Q4 2023 Earnings Call Transcript
ORGO earnings call for the period ending December 31, 2023.
Organogenesis ( ORGO ) Reports Break-Even Earnings for Q4
Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Organogenesis Hldgs ( NASDAQ:ORGO )
NEW YORK, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc.
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
CANTON, Mass., Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( Nasdaq: ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ...
Foghorn Therapeutics Inc. ( FHTX ) Moves 22.7% Higher: Will This Strength Last?
Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Organogenesis Hldgs ( NASDAQ:ORGO )
NEW YORK, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc.
Are You Looking for a Top Momentum Pick? Why Organogenesis ( ORGO ) is a Great Choice
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
ORGO: 3 Biotech Stocks to Keep an Eye on in 2024
ORGO: 3 Biotech Stocks to Keep an Eye on in ...
Advanced Wound Care Market size to grow by USD 4.02 billion from 2022 to 2027, North America to account for 41 ... - PR Newswire
Advanced Wound Care Market size to grow by USD 4.02 billion from 2022 to 2027, North America to account for 41 ... PR ...
Best Momentum Stocks to Buy for January 5th
ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.
